How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area

Table 4

Eligibility criteria for the DECLARE-TIMI 58 trial (dapagliflozin) and number of patients in the SIDIAP database that would have met criteria for enrolment.

Eligibility in the DELCLARE-TIMI 58 trial	Potentially eligible patients from the SIDIAP database ()
Inclusion criteria	In PP, (%)	In SP, (%)
Age:
(i) In PP: ≥55 years; ≥60 in women; (ii) In SP: ≥40	175,092 (46.9); 140,941 (37.8); —	—; 368,963 (98.9)
Primary prevention cohort
≥55 years (≥60 in women) and ≥1 CVRF: (i) Dyslipidemia; (ii) Hypertension; (iii) Current smoker	289,126 (77.5)	—
Secondary prevention cohort
≥40 years and history of CV events (CHD, angina, MI, stroke, and PAD)	—	86,468 (23.2)
HbA1c 6.5%-<12%	165,777 (44.4)	50,872 (13.6)
Main exclusion criteria	In PP	In SP
	53,851 (14.4)	21,145 (5.7)
Total eligible in PP and SP, (%)	111,926 (30)	29,727 (7.9)
Total eligible, (%)	141,653 (38%)

CHD: coronary heart disease; CV: cardiovascular; CVRF: cardiovascular risk factors; eGFR: estimated glomerular filtration rate; MI: myocardial infarction; PAD: peripheral artery disease; PP: primary cardiovascular prevention; SP: secondary cardiovascular prevention; HbA1c: glycated haemoglobin. All the percentages refer to the proportion from the total number of eligible subjects of the SIDIAP database ().